ProMIS Neurosciences Inc
TSX:PMN

Watchlist Manager
ProMIS Neurosciences Inc Logo
ProMIS Neurosciences Inc
TSX:PMN
Watchlist
Price: 6 CAD -3.85% Market Closed
Market Cap: 51.5m CAD

ProMIS Neurosciences Inc
Net Issuance of Common Stock

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ProMIS Neurosciences Inc
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
ProMIS Neurosciences Inc
TSX:PMN
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Repare Therapeutics Inc
NASDAQ:RPTX
Net Issuance of Common Stock
$110k
CAGR 3-Years
-90%
CAGR 5-Years
-79%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Net Issuance of Common Stock
-$114.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-48%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Net Issuance of Common Stock
$15.7m
CAGR 3-Years
-70%
CAGR 5-Years
-34%
CAGR 10-Years
-10%
Spectral Medical Inc
TSX:EDT
Net Issuance of Common Stock
CA$1.8m
CAGR 3-Years
174%
CAGR 5-Years
-21%
CAGR 10-Years
-11%
No Stocks Found

ProMIS Neurosciences Inc
Glance View

Market Cap
51.5m CAD
Industry
Biotechnology

ProMIS Neurosciences Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario and currently employs 5 full-time employees. The company went IPO on 2005-09-30. ProMIS Neurosciences, Inc. is a Canada-based development-stage biotechnology company. The firm is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The firm is focused on the discovery engine, which is based on the use of two complementary algorithms: ProMIS and Collective Coordinates, which are used to predict targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. The firm is focused on developing antibody therapeutics for AD, ALS and PD. The firm has a wholly owned subsidiary is ProMIS Neurosciences (US) Inc. (ProMIS USA).

PMN Intrinsic Value
Not Available

See Also

Back to Top